Latest Streptococcus pneumoniae Stories
LONDON, Dec. 3, 2014 /PRNewswire/ -- SummaryThe active pharmaceutical ingredients worldwide market is in continuous development from the recent years.
A 10-valent pneumococcal conjugate vaccine (PCV) is effective in reducing the number of new cases of likely-bacterial community-acquired pneumonia in infants in Latin America.
In response to an article published by Healio Pediatrics, Dr.
Children who receive a vaccine to prevent blood and ear infections, appear to be reducing the spread of pneumonia to the rest of the population, especially their grandparents and other older adults.
It's been known for more than two centuries that pneumonia cases increase during flu epidemics.
A new study led by researchers from Harvard School of Public Health (HSPH) and the Wellcome Trust Sanger Institute in the UK has, for the first time, used genome sequencing technology to track the changes in a bacterial population following the introduction of a vaccine.
Streptococcus pneumoniae, or pneumococcus, is Gram-positive, alpha-hemolytic, bile-soluble aerotolerant, anaerobic member of the genus Streptococcus. It was recognized as a major cause of pneumonia in the late 19th century and is thus the subject of many humoral immunity studies. It causes many other types of pneumococcal infections other than pneumonia including acute sinusitis, otitis media, meningitis, bacteremia, sepsis, septic arthritis, peritonitis, cellulites, and brain abscess. It...